March 4, 2013 - Atlanta, GA. The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at risk of HIV infection. Continue Reading...
Do you get our newsletter?
Sign up for our monthly Newsletter and get the latest info in you in box.
Feeling low? Learn about depression – what it is, its symptoms, why HIV+ women are likely to have it, and why it is important to find and treat.
Learn about your liver's functions, symptoms and tests for liver damage, which HIV drugs affect the liver, and how to keep your liver healthy.